Document:

exv10w26

 

Exhibit 10.26

ANTEX BIOLOGICS INC.

THIS PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW AND MAY NOT BE
SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE
SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR ANTEX BIOLOGICS
INC. SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH
SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE
STATE SECURITIES LAWS IS NOT REQUIRED.

PROMISSORY NOTE

	 	 	 
	U.S. $145,500

Gaithersburg, MD	 	
Date: December 12, 2002

     1.     Amount. Antex Biologics Inc., a Delaware corporation having its
principal place of business located at 300 Professional Drive, Gaithersburg, MD
20879 (the “Borrower”), for value received, hereby promises to pay to the order
of DMG Legacy International Ltd., a British Virgin Islands corporation having
its principal place of business at 53 Forest Avenue, Suite 202, Old Greenwich,
Connecticut 06870 (the “Lender”), the amount of one hundred and forty five
thousand five hundred U.S. Dollars (US $145,500) (the “Principal”), plus an
annual interest on the Principal of Ten Percent (10%) (the “Interest”).

     2.     Payment. Any unpaid Principal and Interest on this Promissory Note
will become due and payable on February 15, 2003. At such time the Borrower
shall repay the unpaid Principal and accrued Interest on this Promissory Note.
All such payments shall be made in same day funds denominated in United States
Dollars. In the event the Borrower completes a Financing of at least
$2,000,000 prior to February 15, 2003 with entities other than the Lender or
its affiliates, then the Borrower shall repay the unpaid Principal and accrued
Interest on this Promissory Note upon the closing of the Financing.

     3.     Interest. Interest on the outstanding principal balance of this
Promissory Note shall accrue at a rate of ten percent (10%) per annum.
Interest on the outstanding principal balance of the Promissory Note shall be
computed on the basis of the actual number of days elapsed and a year of three
hundred and sixty (360) days.

     4.     Prepayment. The Borrower may prepay without penalty all or any
portion of the sums owed hereunder.

     5.     Presentment. The Borrower (i) waives presentment, demand, protest and
notice of presentment, notice of protest and notice of any kind respecting this
Promissory Note; and (ii) agrees that this Promissory Note shall be binding
upon the Borrower and the Borrower’s successors and assigns.

     6.     Replacement. Upon receipt of a duly executed, notarized and unsecured
written statement from the Lender with respect to the loss, theft or
destruction of this Promissory Note (or any replacement hereof), and without
requiring an indemnity bond or other security, or, in the case of a mutilation
of this Promissory Note, upon surrender and cancellation of such Promissory

 

 

Note, the Borrower shall issue a new Promissory Note, of like tenor and amount,
in lieu of such lost, stolen, destroyed or mutilated Promissory Note.

     7.     Severability. In the event any one or more of the provisions
contained in this Promissory Note shall for any reason be held to be invalid,
illegal or unenforceable in any respect, such invalidity, illegality or
unenforceability shall, at the option of the Lender or any holder hereof, not
affect any other provision of this Promissory Note, but this Promissory Note
shall be construed as if such invalid, illegal or unenforceable provision had
never been contained herein.

     8.     Compliance with Securities Laws. The Lender of this Promissory Note
acknowledges that this Promissory Note is being acquired solely for the
Lender’s own account and not as a nominee for any other party, and for
investment, and that the Lender shall not offer, sell or otherwise dispose of
this Promissory Note other than in compliance with the laws of the United
States of America and as guided by the rules of the Securities and Exchange
Commission. This Promissory Note and any Promissory Note issued in
substitution or replacement therefore shall be stamped or imprinted with a
legend in substantially the following form:

		
	 	“THIS PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE
SECURITIES LAW AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE
DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER
APPLICABLE STATE SECURITIES LAWS OR ANTEX BIOLOGICS INC. SHALL
HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH
SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF
APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.”

     9.     Modification. This Promissory Note may only be modified by an
agreement in writing executed by the Borrower and Lender. The Borrower has the
full power, authority and legal right to execute and deliver this Promissory
Note, and represents that this Promissory Note constitutes a valid and binding
obligation of the Borrower.

     10.     Waivers. Any failure of the Lender to exercise any right hereunder
shall not be construed as a waiver of the right to exercise the same or any
other right at any other time.

     11.     Enforcement Expenses. The Borrower agrees to pay all costs and
expenses of enforcement of this Promissory Note, including, without limitation,
reasonable attorneys’ fees and expenses.

     12.     Terms Defined. The terms “Borrower” and “Lender” as used in this
Promissory Note shall include their respective heirs, executors, personal
representatives, successors and assigns.

     13.     Binding Effect. The obligations of the Borrower and the Lender set
forth herein shall be binding upon the successors and assigns of each such
party.

     14. Controlling Law. This Promissory Note shall be governed by the laws
of the United States of America and the State of New York, without regard to
the principles of conflicts laws of those jurisdictions.

 

 

     IN WITNESS WHEREOF, the Borrower has executed and delivered this
Promissory Note as of the date first written above.

	 
	Antex Biologics Inc.

A Delaware Corporation
	 
	By: /s/ Jeffrey Pirone       
              

       Name:  Jeffrey Pirone

       Title:  Executive Vice Presidentexv10w27

 

Exhibit 10.27

ANTEX BIOLOGICS INC.

THIS PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW AND MAY NOT BE
SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE
SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR ANTEX BIOLOGICS
INC. SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH
SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE
STATE SECURITIES LAWS IS NOT REQUIRED.

PROMISSORY NOTE

	 	 	 
	U.S. $200,000

Gaithersburg, MD	 	
Date: December 26, 2002

     1.     Amount. Antex Biologics Inc., a Delaware corporation having its
principal place of business located at 300 Professional Drive, Gaithersburg, MD
20879 (the “Borrower”), for value received, hereby promises to pay to the order
of Erica Jesselson, an individual having her principal place of business at 450
Park Avenue, New York, NY 10022 (the “Lender”), the amount of two hundred
thousand U.S. Dollars (US $200,000) (the “Principal”), plus an annual interest
on the Principal of Ten Percent (10%) (the “Interest”).

     2.     Payment. Any unpaid Principal and Interest on this Promissory Note
will become due and payable on January 15, 2003. At such time the Borrower
shall repay the unpaid Principal and accrued Interest on this Promissory Note.
All such payments shall be made in same day funds denominated in United States
Dollars.

     3.     Interest. Interest on the outstanding principal balance of this
Promissory Note shall accrue at a rate of ten percent (10%) per annum.
Interest on the outstanding principal balance of the Promissory Note shall be
computed on the basis of the actual number of days elapsed and a year of three
hundred and sixty (360) days.

     4.     Extension. The Borrower, at its option, may extend the maturity date
of the Promissory Note from January 15, 2003 until February 15, 2003 without
penalty. In the event that the maturity date is extended pursuant to this
section 4., the interest rate for the extension period shall increase from ten
percent (10%) to eleven percent (11%) per annum.

     5.     Prepayment. The Borrower may prepay without penalty all or any
portion of the sums owed hereunder.

     6.     Presentment. The Borrower (i) waives presentment, demand, protest and
notice of presentment, notice of protest and notice of any kind respecting this
Promissory Note; and (ii) agrees that this Promissory Note shall be binding
upon the Borrower and the Borrower’s successors and assigns.

     7.     Replacement. Upon receipt of a duly executed, notarized and unsecured
written statement from the Lender with respect to the loss, theft or
destruction of this Promissory Note (or any replacement hereof), and without
requiring an indemnity bond or other security, or, in the

 

 

case of a mutilation of this Promissory Note, upon surrender and cancellation
of such Promissory Note, the Borrower shall issue a new Promissory Note, of
like tenor and amount, in lieu of such lost, stolen, destroyed or mutilated
Promissory Note.

     8.     Severability. In the event any one or more of the provisions contained
in this Promissory Note shall for any reason be held to be invalid, illegal or
unenforceable in any respect, such invalidity, illegality or unenforceability
shall, at the option of the Lender or any holder hereof, not affect any other
provision of this Promissory Note, but this Promissory Note shall be construed
as if such invalid, illegal or unenforceable provision had never been contained
herein.

     9.     Compliance with Securities Laws. The Lender of this Promissory Note
acknowledges that this Promissory Note is being acquired solely for the
Lender’s own account and not as a nominee for any other party, and for
investment, and that the Lender shall not offer, sell or otherwise dispose of
this Promissory Note other than in compliance with the laws of the United
States of America and as guided by the rules of the Securities and Exchange
Commission. This Promissory Note and any Promissory Note issued in
substitution or replacement therefore shall be stamped or imprinted with a
legend in substantially the following form:

		
	 	“THIS PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE
SECURITIES LAW AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE
DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER
APPLICABLE STATE SECURITIES LAWS OR ANTEX BIOLOGICS INC. SHALL
HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH
SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF
APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.”

     10.     Modification. This Promissory Note may only be modified by an
agreement in writing executed by the Borrower and Lender. The Borrower has the
full power, authority and legal right to execute and deliver this Promissory
Note, and represents that this Promissory Note constitutes a valid and binding
obligation of the Borrower.

     11.     Waivers. Any failure of the Lender to exercise any right hereunder
shall not be construed as a waiver of the right to exercise the same or any
other right at any other time.

     12.     Enforcement Expenses. The Borrower agrees to pay all costs and
expenses of enforcement of this Promissory Note, including, without limitation,
reasonable attorneys’ fees and expenses.

     13.     Terms Defined. The terms “Borrower” and “Lender” as used in this
Promissory Note shall include their respective heirs, executors, personal
representatives, successors and assigns.

     14.     Binding Effect. The obligations of the Borrower and the Lender set
forth herein shall be binding upon the successors and assigns of each such
party.

 

 

     15.     Controlling Law. This Promissory Note shall be governed by the laws
of the United States of America and the State of New York, without regard to
the principles of conflicts laws of those jurisdictions.

     IN WITNESS WHEREOF, the Borrower has executed and delivered this
Promissory Note as of the date first written above.

	 
	Antex Biologics Inc.

A Delaware Corporation
	 
	By: /s/ Jeffrey Pirone       
              

       Name:  Jeffrey Pirone

       Title:  Executive Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00046-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00046-of-00352.parquet"}]]